Halozyme Therapeutics, Inc. (HALO)

From the record

Halozyme Therapeutics, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Halozyme Therapeutics, Inc.'s 9 filed years say what it did: revenue went from $317 million in fiscal 2017 to $1.4 billion in fiscal 2025, up 20.4% a year; it rose in 7 of 8 years; the deepest fall was 52% from fiscal 2017 to fiscal 2018; net income was positive in 7 of 9 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Halozyme Therapeutics, Inc.'s diluted share count shrank about 4.1% a year, and dividends and buybacks returned about 65% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 106 sales (102 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-10-08 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Halozyme Therapeutics, Inc. earned about 649 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 46 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 98 cents per dollar of assets, and net share issuance: its share count shrank 4.3% over the year (the filed statements).

From the record

Halozyme Therapeutics, Inc.'s standing among 102 graded names in its industry family: revenue of $1.4 billion in fiscal 2025 ranks in the top 7% by size; a net margin of 22.7% ranks in the top 12%; revenue growth of 28.4% a year over the last 3 filed years ranks in the top 27% (its annual reports).

From the record

Halozyme Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Torley, Helen (PRESIDENT AND CEO, as filed), filing under that title since 2014-01-08, 12.8 years (top 5% of its family); the 14 officers and directors filing in the last fifteen months have been on the record a median of 4.8 years (bottom 33%); 12 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (bottom 21%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Halozyme Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $134 million against debt of $2.1 billion leaves -79.5% of its assets as net cash, bottom 1% of its family; cash from operations less capital spending is 46.2% of revenue (top 2%); a gross margin of 83.6% (top 31%); research spending of 5.8% of revenue (bottom 3%) (its annual report).

From the record

Halozyme Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 28.4% a year over the last three filed years against 20.4% over all 9, speeding up (top 17% of its family); the newest year grew 37.6% (top 36%); research spending grew 3.3% a year (top 45%); capital spending grew 13.2% a year (top 22%) (its annual reports). Halozyme Therapeutics, Inc. reported 8 product lines in fiscal 2025: Royalty at $868 million (62%), Proprietary Products Sales at $195 million (14%), Bulk R Hu PH20 at $133 million (10%), and 5 more; 5 of 8 grew against the year before (its annual report).

From the record

Halozyme Therapeutics, Inc.'s newest year against its own record: revenue of $1.4 billion in fiscal 2025 came in 10.9% above the $1.3 billion its prior three years' pace pointed to (top 40% of its family); net income of $317 million against a prior three-year average of $309 million (bottom 45%); a net margin of 22.7% against 36.1% before (bottom 28%) (its annual reports).